| Vaccine | Brand on Formulary | Dose & Timing | Notes |
|---|---|---|---|
| Pneumococcal conjugate 13-valent (Pneu-C-13) vaccine | Prevnar-13 | 0.5 mL deep IM (deltoid) x 1 dose | Must wait at least 1 year after any dose of Pneu-P-23 before giving Pneu-C-13.* |
| Pneumococcal polysaccharide 23-valent (Pneu-P-23) vaccine | Pneumovax-23 | 0.5 mL SC/IM x 1 dose Booster after 5 years |
Must wait at least 8 weeks after any dose of Pneu-C-13 before giving Pneu-P-23. |
| Meningococcal quadrivalent conjugate (Men-C-ACYW) vaccine | Menactra | 0.5 mL IM (deltoid preferred) x 2 doses at least 8 weeks apart Booster every 5 years |
|
| Multicomponent meningococcus serogroup B (4CMenB) vaccine | Bexsero | 0.5 mL IM given x2 doses at least 4 weeks apart | Not part of the routine immunization schedule, but recommended for high-risk individuals. |
| Haemophilus b (Hib) conjugate vaccine | Act-HIB | 0.5 mL IM x 1 dose | |
| Influenza vaccine | varies | given annually |
* NACI recommends administration of Pneu-C-13 (Prevnar-13) at least one year after any previous dose of Pneu-P-23 (Penumovax-23) vaccine, due to the theoretical potential for decrease in antibody titers following immunization with Pneu-P-23 vaccine.
| Date (Scheduled Surgery) | Date (Emergent Surgery) | Vaccines |
|---|---|---|
| 10 weeks prior to surgery | 2 weeks after splenectomy | Pneu-C-13 (Prevnar-13) Men-C-ACYW (Menactra) 4CMenB (Bexsero) Hib (Act-HIB) |
| 2 weeks prior to surgery | 10 weeks after splenectomy | Pneu-P-23 (Pneumovax-23) Men-C-ACYW (Menactra) 4CMenB (Bexsero) |
| Routine follow-up | Routine follow-up | Annual influenza immunization Pneu-P-23 (Pneumovax-23) booster at 5 years Men-C-ACYW (Menactra) booster every 5 years |
Immunization of persons with chronic diseases. In: Canadian Immunization Guide. May 2022.
Canadian National Advisory Council on Immunization (NACI), Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135, May 2007.
Canadian National Advisory Council on Immunization (NACI), Update on meningococcal disease and meningococcal vaccine conjugate recommendations, April 2009.
Canadian National Advisory Council on Immunization (NACI), Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older – Interim Recommendation, October 2016.
Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Adults Aged 19 Years and Older — United States, 2013;62(01):9-19. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/su6201a3.htm.